Stock Chart

ANNX

$4.12 -2.60%
Score: 65.7 HOLD
Pro
Screener
Vol: 1.17x (vs SPY: 1.1x | vs QQQ: 1.1x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Oct 01, 2026
Bear Pennant Bearish scenario quality 62/100 deep retrace
Setup invalidates on a close above $4.41 · pole −28% — no price target (measured-move targets failed our backtest for flags/pennants)
Historically breaks down 70% of the time (n=1,730). Measured-move targets failed our backtest — none shown.
Pattern detection is automated and probabilistic — a scenario map for levels, not a buy/sell signal. Rails, projected path and invalidation level are drawn on the chart below.
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About ANNX - Annexon, Inc. Common Stock

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product …

Key Statistics

Market Cap $802M

This ANNX stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track ANNX's price movements with trendlines, gamma walls, and key support/resistance levels.